<?xml version='1.0' encoding='utf-8'?>
<document id="20960028"><sentence text="Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors."><entity charOffset="38-47" id="DDI-PubMed.20960028.s1.e0" text="sunitinib" /><entity charOffset="68-78" id="DDI-PubMed.20960028.s1.e1" text="pemetrexed" /><pair ddi="false" e1="DDI-PubMed.20960028.s1.e0" e2="DDI-PubMed.20960028.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20960028.s1.e0" e2="DDI-PubMed.20960028.s1.e1" /></sentence><sentence text="Sunitinib is an oral multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors, as well as of other receptor types"><entity charOffset="0-9" id="DDI-PubMed.20960028.s2.e0" text="Sunitinib" /><entity charOffset="35-43" id="DDI-PubMed.20960028.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.20960028.s2.e0" e2="DDI-PubMed.20960028.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20960028.s2.e0" e2="DDI-PubMed.20960028.s2.e1" /></sentence><sentence text=" We have performed a feasibility study to investigate the safety of sunitinib in combination with pemetrexed for treatment of advanced refractory solid tumors"><entity charOffset="68-77" id="DDI-PubMed.20960028.s3.e0" text="sunitinib" /><entity charOffset="98-108" id="DDI-PubMed.20960028.s3.e1" text="pemetrexed" /><pair ddi="false" e1="DDI-PubMed.20960028.s3.e0" e2="DDI-PubMed.20960028.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20960028.s3.e0" e2="DDI-PubMed.20960028.s3.e1" /></sentence><sentence text="" /><sentence text="Sunitinib was administered once daily on a continuous daily dosing (CDD) schedule (37"><entity charOffset="0-9" id="DDI-PubMed.20960028.s5.e0" text="Sunitinib" /></sentence><sentence text="5 mg/day) or a 2-weeks-on, 1-week-off treatment schedule (50 mg/day, Schedule 2/1) in combination with pemetrexed at 500 mg/m(2) on day 1 of repeated 21-day cycles"><entity charOffset="103-113" id="DDI-PubMed.20960028.s6.e0" text="pemetrexed" /></sentence><sentence text="" /><sentence text="Twelve patients were enrolled in the study: six on the CDD schedule and six on Schedule 2/1" /><sentence text=" None of the treated patients experienced a dose-limiting toxicity" /><sentence text=" Toxicities were manageable and similar in type to those observed in monotherapy studies of sunitinib and pemetrexed"><entity charOffset="92-101" id="DDI-PubMed.20960028.s10.e0" text="sunitinib" /><entity charOffset="106-116" id="DDI-PubMed.20960028.s10.e1" text="pemetrexed" /><pair ddi="false" e1="DDI-PubMed.20960028.s10.e0" e2="DDI-PubMed.20960028.s10.e0" /><pair ddi="false" e1="DDI-PubMed.20960028.s10.e0" e2="DDI-PubMed.20960028.s10.e1" /></sentence><sentence text=" Pharmacokinetic analysis did not reveal any substantial drug-drug interaction" /><sentence text=" One patient with squamous cell lung cancer showed a partial response and five patients had stable disease" /><sentence text="" /><sentence text="Combination therapy with sunitinib administered on Schedule 2/1 (50 mg/day) or a CDD schedule (37"><entity charOffset="25-34" id="DDI-PubMed.20960028.s14.e0" text="sunitinib" /></sentence><sentence text="5 mg/day) together with standard-dose pemetrexed (500 mg/m(2)) was well tolerated in previously treated patients with advanced solid tumors"><entity charOffset="38-48" id="DDI-PubMed.20960028.s15.e0" text="pemetrexed" /></sentence><sentence text="" /></document>